Please login to the form below
Medicare
This page shows the latest Medicare news and features for those working in and with pharma, biotech and healthcare.
Novartis sues US government over Medicare drug price negotiation programme
Administration (FDA) to treat heart failure, with around 587, 000 Medicare patients taking the drug every year. ... Collectively, the drugs accounted for more than $45bn in Medicare Part D spending from June 2022 to May 2023, according to the CMS.
Latest news
-
US government announces first ten drugs subject to Medicare pricing negotiations
The IRA allows Medicare, the government health plan for older adults, to negotiate lower prices for a selected group of prescription medicines. ... Collectively, the drugs accounted for more than $45bn in Medicare Part D spending from June 2022 to May
-
AstraZeneca latest to sue US government over Medicare drug price negotiation plan
AstraZeneca (AZ) has sued the US government over “critical aspects” of the Medicare drug price negotiation element of President Biden's Inflation Reduction Act (IRA). ... The IRA allows Medicare, the government health plan for older adults, to
-
Being the change
Innovation reduction. The deep dive was about the implications of the Inflation Reduction Act, the recent US legislation that allows Medicare to negotiate the prices of some innovative drugs. ... Stepping back. We began by putting the act in perspective.
-
Boehringer sues US government over Medicare drug price negotiation programme
The IRA allows Medicare, the government health plan for older adults, to negotiate lower prices for a selected group of prescription medicines. ... The drugmaker also alleges that the programme does not involve “genuine negotiations” between drug
-
Tooth and nail
For some context, the Inflation Reduction Act (IRA), which was passed in 2022, gives Medicare the right to negotiate some (not all) drug prices with manufacturers. ... Lawyers from both Merck and BMS claim that the Medicare-negotiation programme is
More from news
Approximately 13 fully matching, plus 168 partially matching documents found.
Latest Intelligence
-
How diversity and inclusion continues to be incorporated in dermatology
References. 1 Takeshita J, Gelfand JM, Li P, et al. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.
-
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Between 2012 and 2016, annual spending on biologic drugs in the US nearly doubled, with unit prices accounting for 56% of the spending increase within Medicare Part D and 20% in ... In Medicare Part B, legislation could be passed to encourage physician
-
Eliminating pharmaceutical rebates, is this déjà vu?
Due to consolidation in the industry, most prescription drug benefits, including Medicare Part D benefits, are administered by several significant PBMs. ... Completely eliminating Medicare Part D rebates within PBMs is not essential for lowering the
-
The global antibiotic crisis: a 2020 perspective
2020. It seeks to incentivise drug developers by changing the way Medicare reimburses hospitals for treating patients with bacterial infections.
-
Will biosimilars ever catch on in the US?
Others call for more involvement from equally relevant and powerful government bodies, such as Congress, the Centers for Medicare and Medicaid Services, the US Patent and Trademark Office and the US
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
PhRMA appoints senior government affairs position
During this time, he worked on Medicare and issues related to the FDA.
-
Former FDA head to join J&J
He has additional senior experience in government, serving as the administrator of the Centers for Medicare &Medicaid Services for the US Department of Health and Human Services from 2004 to 2006.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
The increasing influence of the Centers for Medicare and Medicaid Services on the commercialization of oncology products.
-
The challenges of reimbursement and innovative pricing for cell and gene therapies
Research from Avalere shows that since the CAR-T product launched in 2017, “concerns have persisted over how the Medicare program would reimburse for these products, which are currently administered in
-
A new prescription for the U.S. healthcare market?
Government to negotiate the price of some medicines purchased by Medicare, the national health insurance programme that supports over 60 million people in the U.S. ... cap on annual “out of pocket” costs borne by Medicare’s patients and enforcing
-
Data-driven policy and market access firm Avalere joins Fishawack Health
2. Registry and 100% sample of Medicare Fee-for-Service (FFS) dataset. The MORE.
-
Robust Review: Pricing & Market Access
To better assess the acceptability of their product, they leveraged Rapid Payer Response (RPR) to elicit insights from both the Medicare and the Commercial perspective by engaging with a large sample
More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
SEVEN STONES COLLECTIVE
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
